Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Harold J. Burstein
Abstract
ER-positive, HER2-negative breast cancer, which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy is the cornerstone of systemic therapy, and its efficacy depends on such factors as grade, Ki-67 labeling, and progesterone receptor expression.
Topics & Concepts
AntiestrogenBreast cancerSystemic therapyEstrogen receptorMedicineOncologyInternal medicineEstrogenCancerProgesterone receptorCancer researchAdvanced Breast Cancer TherapiesBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research